KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNTech SE (BNTX) Research & Development (2018 - 2025)

BioNTech SE's Research & Development history spans 8 years, with the latest figure at -$588.3 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 10.01% to -$588.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.4 billion, a 2.51% increase, with the full-year FY2025 number at -$2.4 billion, up 1.27% from a year prior.
  • Research & Development hit -$588.3 million in Q4 2025 for BioNTech SE, up from -$660.3 million in the prior quarter.
  • Over the last five years, Research & Development for BNTX hit a ceiling of -$242.2 million in Q2 2021 and a floor of -$660.3 million in Q3 2025.
  • Historically, Research & Development has averaged -$473.9 million across 5 years, with a median of -$531.1 million in 2022.
  • Biggest five-year swings in Research & Development: plummeted 101360660.56% in 2021 and later grew 10.01% in 2025.
  • Tracing BNTX's Research & Development over 5 years: stood at -$310.6 million in 2021, then tumbled by 67.46% to -$520.1 million in 2022, then decreased by 19.53% to -$621.7 million in 2023, then dropped by 5.16% to -$653.8 million in 2024, then rose by 10.01% to -$588.3 million in 2025.
  • Business Quant data shows Research & Development for BNTX at -$588.3 million in Q4 2025, -$660.3 million in Q3 2025, and -$576.3 million in Q2 2025.